<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031144</url>
  </required_header>
  <id_info>
    <org_study_id>KUMC 2019-05-008</org_study_id>
    <nct_id>NCT04031144</nct_id>
  </id_info>
  <brief_title>Ultrafiltration on Coagulation Function in Cardiac Surgery</brief_title>
  <official_title>Effect of Ultrafiltration Before Weaning From Cardiopulmonary Bypass on Post-bypass Coagulation Function in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of microfiltration, which is usually employed for reducing free water&#xD;
      at the end of cardiopulmonary bypass (CPB), on post-CPB coagulation profile in patients&#xD;
      undergoing cardiac surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients with reduced clot strength (in MCF in ROTEM-EXTEM and its value will be determined by Youden's J statistic) before applying ultrafiltration at the end of cardiopulmonary bypass Patients who undergo cardiac surgery with cardiopulmonary bypass</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal clot formation (MCF) in rotational thromboelastometry, EXTEM</measure>
    <time_frame>5 min-before and 5 min-after applying ultrafiltration</time_frame>
    <description>change of MCF (delta-MCF) before and after applying ultrafiltration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clotting time (CT) in rotational thromboelastometry, EXTEM</measure>
    <time_frame>5 min-before and 5 min-after applying ultrafiltration</time_frame>
    <description>change of CT (delta-CT) before and after applying ultrafiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal clot formation at 5 min (A5) in rotational thromboelastometry, FIBTEM</measure>
    <time_frame>5 min-before and 5 min-after applying ultrafiltration</time_frame>
    <description>change of A5 (delta-A5) before and after applying ultrafiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of lysis (lysis%) in rotational thromboelastometry, EXTEM</measure>
    <time_frame>5 min-before and 5 min-after applying ultrafiltration</time_frame>
    <description>change of lysis% (delta-lysis%) before and after applying ultrafiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit (Hct)</measure>
    <time_frame>5 min-before and 5 min-after applying ultrafiltration</time_frame>
    <description>change of Hct (delta-act) before and after applying ultrafiltration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Cardiac Valve Disease</condition>
  <arm_group>
    <arm_group_label>Ultrafiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrafiltration is applied at the end of cardiopulmonary bypass. Maximal clot formation (MCF) of ROTEM-EXTEM tracing is reduced before applying the ultrafiltration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrafiltration</intervention_name>
    <description>At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.</description>
    <arm_group_label>Ultrafiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients undergoing elective cardiac surgery with cardiopulmonary bypass (CPB)&#xD;
&#xD;
          -  maximal clot formation (MCF) in ROTEM-EXTEM is reduced&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MCF &gt; 50 mm before applying ultrafiltration&#xD;
&#xD;
          -  transfusion of packed RBC&gt; 3 units during CPB&#xD;
&#xD;
          -  total ultrafiltration volume &lt; 250 ml&#xD;
&#xD;
          -  hyperfibrinolysis (lysis% &gt; 10%) before applying ultrafiltration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seong-Ho Lee</last_name>
    <phone>82-2-2030-6542</phone>
    <email>20190508@kuh.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Ho Lee</last_name>
      <phone>82-2-2030-6542</phone>
      <email>20190508@kuh.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>coagulation</keyword>
  <keyword>ultrafiltration</keyword>
  <keyword>cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

